Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.
Hebbar M, Chibaudel B, André T, Mineur L, Smith D, Louvet C, Dutel JL, Ychou M, Legoux JL, Mabro M, Faroux R, Auby D, Brusquant D, Khalil A, Truant S, Hadengue A, Dalban C, Gayet B, Paye F, Pruvot FR, Bonnetain F, Landi B, Flesch M, Carola E, Martin P, Vaillant E, de Gramont A; Group Coopérateur Multidisciplinaire en Oncologie (GERCOR) Group. Hebbar M, et al. Among authors: mabro m. Ann Oncol. 2015 Feb;26(2):340-7. doi: 10.1093/annonc/mdu539. Epub 2014 Nov 17. Ann Oncol. 2015. PMID: 25403578 Free article. Clinical Trial.
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A. André T, et al. Among authors: mabro m. Eur J Cancer. 1999 Sep;35(9):1343-7. doi: 10.1016/s0959-8049(99)00150-1. Eur J Cancer. 1999. PMID: 10658525 Clinical Trial.
[Aspirin against cancer].
Mabro M, de Gramont A. Mabro M, et al. Rev Med Interne. 2000 Mar;21 Suppl 1:60s-67s. doi: 10.1016/s0248-8663(00)88726-3. Rev Med Interne. 2000. PMID: 10763206 Review. French.
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M. Maindrault-Goebel F, et al. Among authors: mabro m. Ann Oncol. 2000 Nov;11(11):1477-83. doi: 10.1023/a:1026520812351. Ann Oncol. 2000. PMID: 11142489 Free article. Clinical Trial.
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Mabro M, Artru P, Gilles V, Lotz JP, Izrael V, Krulik M; Oncology Multidisciplinary Research Group (GERCOR). Maindrault-Goebel F, et al. Among authors: mabro m. Eur J Cancer. 2001 May;37(8):1000-5. doi: 10.1016/s0959-8049(01)00068-5. Eur J Cancer. 2001. PMID: 11334725 Clinical Trial.
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
Taïeb J, Artru P, Baujat B, Mabro M, Carola E, Maindrault F, Tournigand C, Krulik M, Louvet C, de Gramont A. Taïeb J, et al. Among authors: mabro m. Eur J Cancer. 2002 Mar;38(5):661-6. doi: 10.1016/s0959-8049(01)00400-2. Eur J Cancer. 2002. PMID: 11916548 Clinical Trial.
49 results